Ann: June Quarterly Update and Appendix 4C, page-7

Yes that is what I thought as well.

I think they brought the quarterly statement out earlier to stem the share price sell-off.

The revenue story is still one of good growth given the delay stated below.
2016 $88 345
2017 $483 235
2018 $2 844 502
2019 $1 937 000 (6 monthly)

On 2 May 2019, 3M announced that it had entered into an agreement to acquire Acelity Inc (andits KCI subsidiaries), (KCI), a leading global medical technology company focused on advancedwound care and specialty surgical applications, predominantly Negative Pressure WoundTherapy (NPWT). The transaction is expected to close in the second half of 2019, subject tocustomary closing conditions and regulatory approvals.
Next Science believes that the integrated 3M KCI sales team will hold a unique opportunity todrive the adoption of BlastX for the treatment of chronic wounds in 2020. However, the delayassociated with the KCI transaction has meant a constrained growth trajectory for BlastX salesin Q2.